Signos

Signos, Inc. is a metabolic health company that sells a subscription membership combining a continuous glucose monitor (CGM) biosensor with an AI-powered mobile app for weight management. Glucose readings are streamed into the app, where they are combined with logged meals, workouts, sleep, hydration and weight data to identify glucose patterns, predict responses to food and movement, and prompt users with in-the-moment adjustments such as a specific type or intensity of activity after a glucose spike. The membership also includes registered dietitian support, daily and weekly metabolism scores, access to a private community, and integrations with Apple Health, Apple Watch, Google Health Connect, smartwatches and smart scales.

The product line spans a core Signos CGM plan, a Signos+ GLP-1 plan for members using GLP-1 medications, and Signos Essentials. The company also offers channels for organizations, including employers, health plans and health partners. The Signos Glucose Monitoring System is described as an over-the-counter mobile application that receives data from an integrated CGM (iCGM) sensor and is intended for people 18 and older who are not on insulin; it measures, records, analyzes and displays glucose values, helps detect normal and dysglycemic levels, and is positioned to help users understand how diet and exercise affect glucose excursions in support of maintaining a healthy weight. The company states the experience is not intended to diagnose, treat, cure or prevent disease, including diabetes, and that users should not take medical action on device output without consulting a healthcare professional. The sensor hardware used is Dexcom's Stelo biosensor, under trademark permission from Dexcom.

The company originally served non-diabetic users and expanded its weight management platform to support people living with Type 2 diabetes in May 2023. In August 2025 Signos received FDA clearance, described in press coverage as the first glucose monitoring system cleared for weight loss/weight management, and it markets the product as HSA/FSA eligible.

Founding story

Sharam Fouladgar-Mercer's long-running interest in his own weight and fitness led him to the idea that glucose could serve as a key biometric to track. A pizza outing with Bill Tancer, who tracked his own weight in spreadsheets, prompted the pair to pursue a data-driven approach to weight management, and they founded Signos to turn personal biodata into actionable guidance.

Business model

Signos sells a direct-to-consumer monthly membership that bundles CGM hardware, the AI app, and registered dietitian support; the site lists a $127/month membership with hardware included and a 30-day results guarantee. Separate plan tiers cover the core CGM program, a GLP-1 companion program, and an Essentials option. The company also markets to organizations — employers, health plans and health partners — and has a distribution arrangement making its subscription plans available through Dexcom's direct-to-consumer site Stelo.com.

Recurring consumer subscription revenue from monthly memberships that include the biosensor hardware and coaching, sold direct on signos.com and, following the 2026 Dexcom agreement, through Stelo.com; the company also pursues organizational channels (employers, health plans, health partners).

Traction

The iOS app holds a 4.6 rating across about 1,000 ratings and the Android app has more than 10,000 downloads. The company's site cites a 4.8 out of 5 review rating and states 86% of members report success in their first month. In May 2026 the CEO said revenue and the user base had each grown roughly tenfold over the prior six months, without disclosing absolute figures, and that tens of thousands of users had participated in clinical studies.

Latest developments

In May 2026 Signos announced a $20 million funding round backed by GV, Dexcom and Blue Cross Blue Shield of Alabama (investing through its 450 Ventures vehicle), together with an expanded Dexcom partnership placing Signos subscription plans on Stelo.com. Proceeds are earmarked in part for predictive AI features including pre-meal glucose-impact scoring. The company declined to disclose its post-round valuation. Coverage of CGMs for weight loss continued into February 2026 with a WIRED feature.